Resources Antibody Industry Trends Week 4, Apr 2024: Fc-Mediated Functions

Week 4, Apr 2024: Fc-Mediated Functions

Biointron 2024-04-23 Read time: 2 mins
Fc.jpg
Uses of antibody-based biologics. DOI: 10.3389/fimmu.2019.01296

Fc-mediated antibody effector functions play an important role in the humoral immune response and form a necessary link between innate and adaptive immunity. The constant (Fc) region is the tail portion of an antibody that interacts with other components of the immune system, such as immune cells and complement proteins. Well-known functions include opsonization, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement activation. 

During last week’s Fc-Mediated Function Summit, researchers explored various aspects of Fc-mediated functions, such as the pathophysiology of FcRn, targeting FcγR for antibody-based immunotherapy, and innovative drug design with Fc Factor 8. The use of Fc biology was clearly demonstrated to have high potential in advancing molecular development, clinical utility, and novel therapeutic applications. 

A study published this month in Nature explores influenza antibody breadth and effector functions as immune correlates from acquisition of pandemic infection of children. In the study, Jia et al. describes how cross-reactive antibodies with FcR effector functions could lessen pandemic virus impact in the absence of neutralizing antibodies. Their results show that seasonal vaccination is beneficial against pandemic influenza viruses. 

Also related to pandemics, a journal pre-proof by Severa et al. highlights how Fc-mediated regulation of antiviral and inflammatory responses, in absence of viral replication, might positively tune immune response during SARS-CoV-2 infection. It may also be exploited in monoclonal antibody-based therapeutic and prophylactic strategies against viral infections.

Subscribe to our Antibody Industry Trends

Recent Antibody Industry Trends

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

Image credit: DOI: 10.1038/s41577-021-00542-xThe progress of COVID-19 therapies has seen remarkable strides, particularly in the development and application of antibody-based treatments. Early in the pandemic, the focus was on supportive care, but the rapid advancement in antibody therapies has sign

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.